VInorelbine Ditartrate Salt Hydrate 酒石酸长春瑞滨
CAS 125317-39-7 MFCD03613607
化学结构图
SMILES: CN1[C@@H]2[C@]3(CCN4CC=C[C@@](CC)([C@@H](OC(C)=O)[C@]2(O)C(=O)OC)[C@@H]34)C2=CC(=C(C=C12)OC)[C@]1(C[C@@H]2C[N@@](CC(CC)=C2)CC2=C1NC1C=CC=CC2=1)C(=O)OC.OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O
化学属性
| Mol. Formula | C45H54N4O8· 2C4H6O6· xH2O |
|---|---|
| Mol. Weight | 1079.11 (anhydrous basis) |
| Melting Point | 181°C-183°C |
别名和识别编码
| Chemical Name | VInorelbine Ditartrate Salt Hydrate |
|---|---|
| CAS Number | 125317-39-7 |
| Synonym | 长春瑞宾双酒石酸盐,酒石酸长春瑞宾 Vinorelbine ditartrate 3,4-Didehydro-4-deoxy-C-norvincaleukoblastine [R-(R*,R*)-2-3-dihydroxybutanedioate (1:2)salt] 3',4'-Didehydro-4'-deoxy-C'-norvincaleukoblastine Ditartrate 3′,4′-Didehydro-4′-deoxy-C′-norvincaleukoblastine [R-(R*,R*)-2-3-dihydroxybutanedioate (1:2)salt] KW-2307 |
| MDL Number | MFCD03613607 |
| PubChem Substance ID | 24724660 |
| Chemical Name Translation | 酒石酸长春瑞滨 |
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
分类
- Pharmaceuticals
- {SNA} Antitumor Agents, Approved Therapeutics/Drug Candidates, Bioactive Small Molecules, Cancer Research, Cell Biology, Cell Signaling and Neuroscience, Cytoskeleton and Extracellular Matrix, Microtubule Inhibitors, Pierre Fabre, V
- {SA} Antitumor Agents, Approved Therapeutics/Drug Candidates, Bioactive Small Molecules, Cancer Research, Cell Biology, Cell Signaling and Neuroscience, Cytoskeleton and Extracellular Matrix, Microtobule Inhibitors, Microtubule Inhibitors, Pierre Fabre, V
- {SNA} Approved Therapeutics/Drug Candidates, Bioactive Small Molecule Alphabetical Index, Cytoskeleton and Extracellular Matrix,
产品应用
- An antineoplastic.
相关文献及参考
- [2]. Liu XM, et al. Unique induction of p21(WAF1/CIP1)expression by vinorelbine in androgen-independent prostate cancer cells. Br J Cancer. 2003 Oct 20;89(8):1566-73.
- [3]. Poirier VJ, et al. Toxicity, dosage, and efficacy of vinorelbine (Navelbine) in dogs with spontaneous neoplasia. J Vet Intern Med. 2004 Jul-Aug;18(4):536-9.
- [4]. Pierro JA, et al. Phase I clinical trial of vinorelbine in tumor-bearing cats. J Vet Intern Med. 2013 Jul-Aug;27(4):943-8.
- Curran, M.P., et al.: Drugs Aging., 19, 695 (2002),
- Levegue, D., et al.: Clin. Pharmacokinet., 31, 184 (1996),
- Mathe, G., et al.: Cancer Letters, 27, 285 (1985),
- [1]. Ngan VK, et al. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic V
- [1]. Ngan VK, et al. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. Mol Pharmacol. 2001 Jul;60(1):225-32.
安全信息
GHS Symbol
- H317 May cause an allergic skin reaction 可能导致皮肤过敏
- S26 In case of contact with eyes, rinse immediately with plenty of water and seek medical advice 眼睛接触后，立即用大量水冲洗并征求医生意见；
- S36 Wear suitable protective clothing 穿戴适当的防护服；
TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rat DOSE : 2 mg/kg SEX/DURATION : female 7-16 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - musculoskeletal system REFERENCE : KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 27,1375,1993
